Literature DB >> 22477826

Carbamazepine-induced acute generalized exanthematous pustulosis: a case report.

Saadia Skalli1, Pierre Barret, Céline Villier, Jean-François Bussières.   

Abstract

A 15-year-old adolescent was admitted to the hospital for management of a generalized pruritic skin rash, which had appeared 10 days prior to admission. Carbamazepine (CBZ) and insulin were initiated 44 and 23 days prior to the onset of the skin rash (day 44), respectively. Clinical examination showed bluish lesions on the tongue and bilateral keratoconjunctivitis. His skin was very erythematous and pruritic without edema and covered with hundreds of nonfollicular pustules mainly on the trunk and skin folds. Laboratory assessment revealed leukocytosis, hypereosinophilia, and thrombocytopenia. A sample of superficial pus from a pustule on the trunk showed a significant number of leukocytes as well as a significant number of Staphylococcus aureus and Lancefield Group B β-hemolytic streptococci strains. An abdominal skin biopsy revealed acute to subacute folliculocentric spongiotic dermatitis with subcorneal pustules. All of these observations were consistent with a diagnosis of acute generalized exanthematous pustulosis (AGEP). Although we could not exclude with certainty the role of insulin initiated on day 21 and discontinued on day 55 with substitution to oral metformin and repaglinide, no cases of AGEP have ever been published with insulin, and skin lesions were not related to injection sites. This article describes a probable case of CBZ-induced acute generalized exanthematous pustulosis in a 15-year-old adolescent.

Entities:  

Year:  2011        PMID: 22477826      PMCID: PMC3136236     

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  14 in total

1.  [Generalized acute exanthematous pustulosis caused by carbamazepine].

Authors:  T Lachgar
Journal:  Allerg Immunol (Paris)       Date:  1999-05

2.  Successful re-introduction of lamotrigine after initial rash.

Authors:  F M Besag; G Y Ng; F Pool
Journal:  Seizure       Date:  2000-06       Impact factor: 3.184

Review 3.  Epicutaneous patch testing.

Authors:  Steven A Devos; Pieter G M Van Der Valk
Journal:  Eur J Dermatol       Date:  2002 Sep-Oct       Impact factor: 3.328

4.  Lamotrigine versus placebo in the prophylaxis of migraine with and without aura.

Authors:  T J Steiner; L J Findley; A W Yuen
Journal:  Cephalalgia       Date:  1997-04       Impact factor: 6.292

Review 5.  Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern.

Authors:  A Sidoroff; S Halevy; J N Bavinck; L Vaillant; J C Roujeau
Journal:  J Cutan Pathol       Date:  2001-03       Impact factor: 1.587

6.  Adverse effects of antiepileptic drugs.

Authors:  E Perucca; K J Meador
Journal:  Acta Neurol Scand Suppl       Date:  2005

7.  Dermatology precautions and slower titration yield low incidence of lamotrigine treatment-emergent rash.

Authors:  Terence A Ketter; Po W Wang; Rebecca A Chandler; Andrea M Alarcon; Olga V Becker; Cecylia Nowakowska; Colette M O'Keeffe; Matthew R Schumacher
Journal:  J Clin Psychiatry       Date:  2005-05       Impact factor: 4.384

8.  Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites.

Authors:  T B Kudriakova; L A Sirota; G I Rozova; V A Gorkov
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 9.  [Drugs associated with acute generalized exanthematic pustulosis].

Authors:  E-H Saissi; F Beau-Salinas; A-P Jonville-Béra; G Lorette; E Autret-Leca
Journal:  Ann Dermatol Venereol       Date:  2003 Jun-Jul       Impact factor: 0.777

Review 10.  Insulin allergy: clinical manifestations and management strategies.

Authors:  L Heinzerling; K Raile; H Rochlitz; T Zuberbier; M Worm
Journal:  Allergy       Date:  2008-02       Impact factor: 13.146

View more
  1 in total

Review 1.  Drug Triggers and Clinic of Acute Generalized Exanthematous Pustulosis (AGEP): A Literature Case Series of 297 Patients.

Authors:  Enriqueta Vallejo-Yagüe; Adrian Martinez-De la Torre; Omar S Mohamad; Shweta Sabu; Andrea M Burden
Journal:  J Clin Med       Date:  2022-01-13       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.